Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases
Report Scope:
This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement, and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2019 and forecast for 2020-2025 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.
The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV, and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions, and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics, and others, are detailed with market data current and forecasts.
Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America, and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States, Europe, Japan, and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to our readers.
Report Includes:
This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement, and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2019 and forecast for 2020-2025 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.
The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV, and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions, and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics, and others, are detailed with market data current and forecasts.
Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America, and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States, Europe, Japan, and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to our readers.
Report Includes:
- 33 data tables and 42 additional tables
- An overview of the global markets for treatment and diagnosis of sexually transmitted diseases
- Analyses of the global market trends, with corresponding market analysis data for 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of the impact of demographic, economic and other factors that will drive future demand for diagnostic and therapeutic interventions affecting sexually transmitted diseases market
- Estimation of market size and forecast the potential market for sexually transmitted disease therapeutics, along with global market share analysis on the basis of disease area and treatments, drug type, and geographical region
- Identification of unmet needs in sexually transmitted diseases therapeutics, promising new drugs and therapies still in the development and testing stage that will be commercialized successfully in the next five years
- Assessment of the long-term outlook for sexually transmitted diseases therapeutics, considering market opportunities as well as technological, financial and economic factors
- Insight into the factors driving and restraining the growth of the global market for treatment and diagnosis of sexually transmitted diseases, along with a regional market overviews for North America, Europe, Asia-Pacific, Latin America and the Middle East
- Company profiles of the leading drug manufacturers and suppliers, market including Abbott Laboratories, AbbVie Inc., Novartis AG, Pfizer Inc., and Thermo Fisher Scientific Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 GLOBAL MARKET OVERVIEW AND TRENDS
Overview of Sexually Transmitted Diseases and Definitions
Sexually Transmitted Diseases and Pregnancy
Screening Programs and Guidelines
Mobile HIV Testing in Brazil
Benzathine Penicillin Drug Shortage
Trends in the Global Transmission of STDs
Increasing Incidence of STDs
STD Awareness and Screening Services
Development of Test Kits with High Sensitivity for Low Resource Settings
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
Rising Incidence of Antibiotic Resistance
Lack of Prenatal Screening for STDs
CHAPTER 4 DISEASE OVERVIEW
Introduction
Chlamydia
Overview
Epidemiology
Diagnosis
Treatments
Genital Herpes
Overview
Epidemiology
Diagnosis
Treatments
Gonorrhea
Overview
Epidemiology
Treatments
Hepatitis A, B and C
Overview
Epidemiology
Diagnosis
Treatments
Market Size
HIV/AIDS
Overview
Epidemiology
Diagnosis
Treatments
Market Size and Forecast
HPV
Overview
Diagnosis
Treatments
Syphilis
Overview
Epidemiology
Diagnosis
Treatments
Others
Overview
Market Analysis
CHAPTER 5 STD DIAGNOSIS AND TREATMENT OPTIONS
Introduction to STD Diagnostics by Test Type
Enzyme Immunoassay (EIA) and ELISA
Polymerase Chain Reaction (PCR)
Rapid Diagnostics Tests (RDTs)
Others
Introduction to Treatment by Drug Class
Antibiotics/Antibacterial
Antiviral/ Antiretrovirals
Others
CHAPTER 6 NORTH AMERICAN MARKET
North American Market
United States
Canada
Mexico
CHAPTER 7 EUROPEAN MARKET
European Market
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
CHAPTER 8 ASIA-PACIFIC MARKET
Introduction
Key Trends in STI Prevention
Asia-Pacific Market
China
Japan
India
South Korea
Rest of Asia-Pacific
CHAPTER 9 REST OF THE WORLD MARKET
Rest of the World Market
CHAPTER 10 REGULATORY STRUCTURE
Overview of Regulations
United States
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
CHAPTER 11 COMPANY PROFILES
ABBOTT LABORATORIES
ABBVIE INC.
AGILENT TECHNOLOGIES INC.
BECTON, DICKINSON AND CO.
BIOMERIEUX INC.
BIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CEPHEID INC.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
HOFFMANN-LA ROCHE INC.
HOLOGIC INC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
PROMEGA CORP.
QIAGEN N.V.
QUIDEL CORP.
THERMO FISHER SCIENTIFIC INC.
CHAPTER 12 APPENDIX
Acronyms
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 GLOBAL MARKET OVERVIEW AND TRENDS
Overview of Sexually Transmitted Diseases and Definitions
Sexually Transmitted Diseases and Pregnancy
Screening Programs and Guidelines
Mobile HIV Testing in Brazil
Benzathine Penicillin Drug Shortage
Trends in the Global Transmission of STDs
Increasing Incidence of STDs
STD Awareness and Screening Services
Development of Test Kits with High Sensitivity for Low Resource Settings
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
Rising Incidence of Antibiotic Resistance
Lack of Prenatal Screening for STDs
CHAPTER 4 DISEASE OVERVIEW
Introduction
Chlamydia
Overview
Epidemiology
Diagnosis
Treatments
Genital Herpes
Overview
Epidemiology
Diagnosis
Treatments
Gonorrhea
Overview
Epidemiology
Treatments
Hepatitis A, B and C
Overview
Epidemiology
Diagnosis
Treatments
Market Size
HIV/AIDS
Overview
Epidemiology
Diagnosis
Treatments
Market Size and Forecast
HPV
Overview
Diagnosis
Treatments
Syphilis
Overview
Epidemiology
Diagnosis
Treatments
Others
Overview
Market Analysis
CHAPTER 5 STD DIAGNOSIS AND TREATMENT OPTIONS
Introduction to STD Diagnostics by Test Type
Enzyme Immunoassay (EIA) and ELISA
Polymerase Chain Reaction (PCR)
Rapid Diagnostics Tests (RDTs)
Others
Introduction to Treatment by Drug Class
Antibiotics/Antibacterial
Antiviral/ Antiretrovirals
Others
CHAPTER 6 NORTH AMERICAN MARKET
North American Market
United States
Canada
Mexico
CHAPTER 7 EUROPEAN MARKET
European Market
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
CHAPTER 8 ASIA-PACIFIC MARKET
Introduction
Key Trends in STI Prevention
Asia-Pacific Market
China
Japan
India
South Korea
Rest of Asia-Pacific
CHAPTER 9 REST OF THE WORLD MARKET
Rest of the World Market
CHAPTER 10 REGULATORY STRUCTURE
Overview of Regulations
United States
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
CHAPTER 11 COMPANY PROFILES
ABBOTT LABORATORIES
ABBVIE INC.
AGILENT TECHNOLOGIES INC.
BECTON, DICKINSON AND CO.
BIOMERIEUX INC.
BIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CEPHEID INC.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
HOFFMANN-LA ROCHE INC.
HOLOGIC INC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
PROMEGA CORP.
QIAGEN N.V.
QUIDEL CORP.
THERMO FISHER SCIENTIFIC INC.
CHAPTER 12 APPENDIX
Acronyms
LIST OF TABLES
Table A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2025
Table B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2025
Table 1: Sexually Transmitted Diseases, by Different Pathogens
Table 2: Global Market for STD Therapeutics, by Disease Area, Through 2025
Table 3: Incidence of Chlamydia, by Country, 2012-2018
Table 4: Chlamydia Diagnostic Products, by Brand Name and Manufacturer
Table 5: Drugs for Chlamydia Treatment
Table 6: Global HSV-1 Prevalence Cases, Aged 0-49 years, by Region, 2016
Table 7: Global HSV-1 Prevalence, Aged 0-49 years, by Region, 2016
Table 8: Genital Herpes Diagnostic Products, by Brand Name and Manufacturer
Table 9: Epidemiology of Gonorrhea, by Country, 2012-2018
Table 10: Gonorrhea Diagnostic Products, by Brand Name and Manufacturer
Table 11: Drug for Gonorrhea Treatment
Table 12: Incidence of Hepatitis A, by Country, 2012-2017
Table 13: Incidence of Hepatitis B, by Country, 2012-2017
Table 14: Incidence of Hepatitis C, by Country, 2012-2015
Table 15: Hepatitis B and C Diagnostic Products, by Brand Name and Manufacturer
Table 16: Hepatitis B Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 17: Hepatitis C Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 18: Global Market for Hepatitis Therapeutics, by Region, Through 2025
Table 19: HIV Prognosis
Table 20: Snapshot of Global HIV Epidemic, by Region, 2019
Table 21: HIV/AIDS Diagnostic Products, by Brand Name and Manufacturer
Table 22: HIV Medications, by Drug Class, Generic Name, and Brand Name
Table 23: Global Market for HIV/AIDS Therapeutics, by Region, Through 2025
Table 24: HPV Diagnostic Products, by Brand Name and Manufacturer
Table 25: HPV Vaccines
Table 26: Incidence of Syphilis, by Country, 2013-2018
Table 27: Syphilis Diagnostic Products, by Brand Name and Manufacturer
Table 28: Drug for Syphilis Treatment
Table 29: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type, and Manufacturer
Table 30: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 31: Global Market for Other Therapeutics, by Region, Through 2025
Table 32: Global Market for STD Diagnostics, by Region, Through 2025
Table 33: Global Market for STD Diagnostics, by Test Type, Through 2025
Table 34: Antibacterial Drugs for Treatment of STDs
Table 35: Global Market for Antibiotics, by Region, Through 2025
Table 36: Global Market for Antiviral/Antiretroviral Drugs, by Region, Through 2025
Table 37: Global Market for Other Drug Classes, by Region, Through 2025
Table 38: North American HBsAG Seroprevalence, by Country, 2016
Table 39: North American Market for STD Therapeutics, by Disease Area, Through 2025
Table 40: North American Market for STD Therapeutics, by Drug Class, Through 2025
Table 41: U.S. Historic and Current Chancroid Trends and Incidence, 1990-2018
Table 42: European Market for STD Therapeutics, by Disease Area, Through 2025
Table 43: European Market for STD Therapeutics, by Drug Class, Through 2025
Table 44: Asia-Pacific Market for STD Therapeutics, by Disease Area, Through 2025
Table 45: Asia-Pacific Market for STD Therapeutics, by Drug Class, Through 2025
Table 46: South American, Middle Eastern and African HIV/AIDS Epidemiology, 2019
Table 47: South American, Middle Eastern and African Market for STD Therapeutics, by Disease Area, Through 2025
Table 48: South American, Middle Eastern and African Market for STD Therapeutics, by Drug Class, Through 2025
Table 49: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 50: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 51: Abbott Laboratories: Marketed Products
Table 52: Abbott Laboratories: Marketed Products, Diagnostics
Table 53: Abbott Laboratories: Financials, 2017-2019
Table 54: AbbVie Inc.: Marketed Products
Table 55: AbbVie Inc.: Financials, 2017-2019
Table 56: Agilent Technologies Inc.: Financials, 2017-2019
Table 57: Becton, Dickinson and Co.: Marketed Products
Table 58: Biomerieux Inc.: Marketed Products
Table 59: Bio-Rad Laboratories: Marketed Products
Table 60: Bristol-Myers Squibb Co.: Marketed Products
Table 61: Bristol-Myers Squibb Company: Financials, 2017-2019
Table 62: Gilead Sciences Inc.: Marketed Products
Table 63: GlaxoSmithKline plc: Marketed Products
Table 64: ViiV Healthcare Group of Companies: Marketed Products
Table 65: Hoffmann-La Roche Inc.: Marketed Products
Table 66: Hologic Inc.: Marketed Products
Table 67: Hologic Inc.: Financials, 2017-2019
Table 68: Merck & Co. Inc.: Marketed Products
Table 69: Novartis AG: Marketed Products
Table 70: Pfizer Inc.: Marketed Products, by Indication
Table 71: Qiagen N.V.: Marketed Products
Table 72: Quidel Corp.: Marketed Products
Table 73: Thermo Fisher Scientific Inc.: Marketed Products
Table 74: Acronyms Used in the Sexually Transmitted Disease Therapeutics and Diagnostics Market
Table A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2025
Table B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2025
Table 1: Sexually Transmitted Diseases, by Different Pathogens
Table 2: Global Market for STD Therapeutics, by Disease Area, Through 2025
Table 3: Incidence of Chlamydia, by Country, 2012-2018
Table 4: Chlamydia Diagnostic Products, by Brand Name and Manufacturer
Table 5: Drugs for Chlamydia Treatment
Table 6: Global HSV-1 Prevalence Cases, Aged 0-49 years, by Region, 2016
Table 7: Global HSV-1 Prevalence, Aged 0-49 years, by Region, 2016
Table 8: Genital Herpes Diagnostic Products, by Brand Name and Manufacturer
Table 9: Epidemiology of Gonorrhea, by Country, 2012-2018
Table 10: Gonorrhea Diagnostic Products, by Brand Name and Manufacturer
Table 11: Drug for Gonorrhea Treatment
Table 12: Incidence of Hepatitis A, by Country, 2012-2017
Table 13: Incidence of Hepatitis B, by Country, 2012-2017
Table 14: Incidence of Hepatitis C, by Country, 2012-2015
Table 15: Hepatitis B and C Diagnostic Products, by Brand Name and Manufacturer
Table 16: Hepatitis B Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 17: Hepatitis C Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 18: Global Market for Hepatitis Therapeutics, by Region, Through 2025
Table 19: HIV Prognosis
Table 20: Snapshot of Global HIV Epidemic, by Region, 2019
Table 21: HIV/AIDS Diagnostic Products, by Brand Name and Manufacturer
Table 22: HIV Medications, by Drug Class, Generic Name, and Brand Name
Table 23: Global Market for HIV/AIDS Therapeutics, by Region, Through 2025
Table 24: HPV Diagnostic Products, by Brand Name and Manufacturer
Table 25: HPV Vaccines
Table 26: Incidence of Syphilis, by Country, 2013-2018
Table 27: Syphilis Diagnostic Products, by Brand Name and Manufacturer
Table 28: Drug for Syphilis Treatment
Table 29: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type, and Manufacturer
Table 30: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 31: Global Market for Other Therapeutics, by Region, Through 2025
Table 32: Global Market for STD Diagnostics, by Region, Through 2025
Table 33: Global Market for STD Diagnostics, by Test Type, Through 2025
Table 34: Antibacterial Drugs for Treatment of STDs
Table 35: Global Market for Antibiotics, by Region, Through 2025
Table 36: Global Market for Antiviral/Antiretroviral Drugs, by Region, Through 2025
Table 37: Global Market for Other Drug Classes, by Region, Through 2025
Table 38: North American HBsAG Seroprevalence, by Country, 2016
Table 39: North American Market for STD Therapeutics, by Disease Area, Through 2025
Table 40: North American Market for STD Therapeutics, by Drug Class, Through 2025
Table 41: U.S. Historic and Current Chancroid Trends and Incidence, 1990-2018
Table 42: European Market for STD Therapeutics, by Disease Area, Through 2025
Table 43: European Market for STD Therapeutics, by Drug Class, Through 2025
Table 44: Asia-Pacific Market for STD Therapeutics, by Disease Area, Through 2025
Table 45: Asia-Pacific Market for STD Therapeutics, by Drug Class, Through 2025
Table 46: South American, Middle Eastern and African HIV/AIDS Epidemiology, 2019
Table 47: South American, Middle Eastern and African Market for STD Therapeutics, by Disease Area, Through 2025
Table 48: South American, Middle Eastern and African Market for STD Therapeutics, by Drug Class, Through 2025
Table 49: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 50: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 51: Abbott Laboratories: Marketed Products
Table 52: Abbott Laboratories: Marketed Products, Diagnostics
Table 53: Abbott Laboratories: Financials, 2017-2019
Table 54: AbbVie Inc.: Marketed Products
Table 55: AbbVie Inc.: Financials, 2017-2019
Table 56: Agilent Technologies Inc.: Financials, 2017-2019
Table 57: Becton, Dickinson and Co.: Marketed Products
Table 58: Biomerieux Inc.: Marketed Products
Table 59: Bio-Rad Laboratories: Marketed Products
Table 60: Bristol-Myers Squibb Co.: Marketed Products
Table 61: Bristol-Myers Squibb Company: Financials, 2017-2019
Table 62: Gilead Sciences Inc.: Marketed Products
Table 63: GlaxoSmithKline plc: Marketed Products
Table 64: ViiV Healthcare Group of Companies: Marketed Products
Table 65: Hoffmann-La Roche Inc.: Marketed Products
Table 66: Hologic Inc.: Marketed Products
Table 67: Hologic Inc.: Financials, 2017-2019
Table 68: Merck & Co. Inc.: Marketed Products
Table 69: Novartis AG: Marketed Products
Table 70: Pfizer Inc.: Marketed Products, by Indication
Table 71: Qiagen N.V.: Marketed Products
Table 72: Quidel Corp.: Marketed Products
Table 73: Thermo Fisher Scientific Inc.: Marketed Products
Table 74: Acronyms Used in the Sexually Transmitted Disease Therapeutics and Diagnostics Market
LIST OF FIGURES
Figure A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2019-2025
Figure B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2019-2025
Figure 1: Death Share Due to Infectious and Parasitic Diseases, 2016
Figure 2: Incidence of Gonorrhea, by Country, 2015-2018
Figure 3: U.S. Funding Trends, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2019
Figure 4: Global Market for STD Therapeutics, 2019-2025
Figure 5: Global Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 6: Global Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 7: Global Historic and Current Chlamydia Trend and Incidence in Women, by Country, 2016-2018
Figure 8: Global Incidence of Gonorrhea in Men, by Country, 2015-2017
Figure 9: Hepatitis Timeline, 1990-2004
Figure 10: Hepatitis Timeline, 2011-2015
Figure 11: Hepatitis Timeline, 2015-2017
Figure 12: Global Market for Hepatitis Therapeutics, 2019-2025
Figure 13: Global Market for Hepatitis Therapeutics, by Region, 2019-2025
Figure 14: Global Market for HIV/AIDS Therapeutics, 2019-2025
Figure 15: Global Market for HIV/AIDS Therapeutics, by Region, 2019-2025
Figure 16: U.S. Incidence of Syphilis Among Newborns, 2016-2018
Figure 17: Global Market for Other Therapeutics, 2019-2025
Figure 18: Global Market for Other Therapeutics, by Region, 2019-2025
Figure 19: Global Market for STD Diagnostics, 2019-2025
Figure 20: Global Market for STD Diagnostics, by Region, 2019-2025
Figure 21: Global Market Shares of STD Diagnostics, by Test Type, 2019
Figure 22: Global Market Shares of STD Diagnostics, by Test Type, 2025
Figure 23: Global Market for EIA and ELISA Diagnostics, 2019-2025
Figure 24: Global Market for PCR Diagnostics, 2019-2025
Figure 25: Global Market for RDT Diagnostics, 2019-2025
Figure 26: Global Market for Other Diagnostics, 2019-2025
Figure 27: Global Market for Antibiotic Drugs, 2019-2025
Figure 28: Global Market for Antibiotic Drugs, by Region, 2019-2025
Figure 29: Global Market for Antiviral/Antiretroviral Drugs, 2019-2025
Figure 30: Global Market for Antiviral/Antiretroviral Drugs, by Region, 2019-2025
Figure 31: Global Market for Other Drug Classes, 2019-2025
Figure 32: Global Market for Other Drug Classes, by Region, 2019-2025
Figure 33: North American Market for STD Therapeutics, 2019-2025
Figure 34: North American Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 35: North American Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 36: North American Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 37: North American Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 38: North American Market for STD Therapeutics, by Country, 2019-2025
Figure 39: U.S. Incidence of STDs, 2018
Figure 40: U.S. Sexually Transmitted Infections, by Sex, 2018
Figure 41: U.S. Historic and Current Syphilis Trends and Incidence, 2000-2018
Figure 42: U.S. Historic and Current Chlamydia Trends and Incidence, 2000-2018
Figure 43: U.S. Historic and Current Gonorrhea Trends and Incidence, 2000-2018
Figure 44: U.S. Historic and Current Hepatitis A Trends and Incidence, 2013-2018
Figure 45: U.S. Historic and Current Acute Hepatitis B Trends and Incidence, 2013-2018
Figure 46: U.S. Historic and Current Hepatitis C Trends and Incidence, 2013-2018
Figure 47: U.S. Historic and Current HIV Trends and Incidence, 2011-2018
Figure 48: U.S. Market for STD Therapeutics, 2019-2025
Figure 49: Canadian Sexually Transmitted Infections, by Sex, 2018
Figure 50: Canadian Historic and Current Chlamydia Trends and Incidence, 2008-2018
Figure 51: Canadian Historic and Current Gonorrhea Trends and Incidence, by Sex, 2008-2018
Figure 52: Canadian Historic and Current Infectious Syphilis Trends and Incidence, 2008-2018
Figure 53: Canadian Historic and Current Congenital Syphilis Trends and Incidence, 2008-2018
Figure 54: Canadian Market for STD Therapeutics, 2019-2025
Figure 55: Mexican Market for STD Therapeutics, 2019-2025
Figure 56: European Historic and Current Chlamydia Trends and Incidence, by Country, 2014-2018
Figure 57: European Historic and Current AIDS Trends and Incidence, by Country, 2014-2018
Figure 58: European Market for STD Therapeutics, 2019-2025
Figure 59: European Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 60: European Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 61: European Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 62: European Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 63: European Market for STD Therapeutics, by Country, 2019-2025
Figure 64: U.K. Incidence of HIV among Gay and Bisexual Men, 2015-2018
Figure 65: U.K. Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 66: U.K. Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 67: U.K. Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 68: U.K. Market for STD Therapeutics, 2019-2025
Figure 69: German Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 70: German Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 71: German Market for STD Therapeutics, 2019-2025
Figure 72: French Historic and Current Chlamydia Trends and Incidence, 2012-2017
Figure 73: French Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 74: French Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 75: French Market for STD Therapeutics, 2019-2025
Figure 76: Spanish Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 77: Spanish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 78: European Centre for Disease Prevention and Control: Annual Epidemiological Report
Figure 79: Spanish Market for STD Therapeutics, 2019-2025
Figure 80: Italian Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 81: Italian Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 82: Italian Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 83: Italian Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 84: Italian Market for STD Therapeutics, 2019-2025
Figure 85: Denmark’s Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 86: The Netherlands Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 87: Denmark’s Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 88: Irish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 89: The Netherlands Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 90: Swedish Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 91: Swedish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 92: Polish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 93: Rest of European Market for STD Therapeutics, 2019-2025
Figure 94: Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 95: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 96: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 97: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 98: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 99: Asia-Pacific Market for STD Therapeutics, by Country, 2019-2025
Figure 100: Chinese Market for STD Therapeutics, 2019-2025
Figure 101: Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2017
Figure 102: Japanese Market for STD Therapeutics, 2019-2025
Figure 103: Indian Historic and Current HIV Trends and Incidence, 2005-2018
Figure 104: Indian Historic and Current HIV Trends and Prevalence, 2005-2018
Figure 105: Indian Historic and Current AIDS Mortality, 2005-2018
Figure 106: Indian Market for STD Therapeutics, 2019-2025
Figure 107: South Korean Historic and Current HIV/AIDS Infections and Incidence, 2001-2018
Figure 108: South Korean Market for STD Therapeutics, 2019-2025
Figure 109: Rest of Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 110: South American, Middle Eastern and African Market for STD Therapeutics, 2019-2025
Figure 111: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 112: South American, Middle Eastern and Africa Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 113: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 114: Abbott Laboratories: Revenue Share, by Region, 2019
Figure 115: Abbott Laboratories: Revenue Share, by Business Segment, 2019
Figure 116: AbbVie Inc.: Revenue Share, by Country, 2019
Figure 117: Agilent Technologies Inc.: Revenue Share, by Region, 2019
Figure 118: Agilent Technologies Inc.: Revenue Share, by Business Segment, 2019
Figure 119: Becton, Dickinson and Co.: Financial Performance, 2013-2019
Figure 120: Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2019
Figure 121: Becton, Dickinson and Co.: Revenue Share, by Region, 2019
Figure A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2019-2025
Figure B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2019-2025
Figure 1: Death Share Due to Infectious and Parasitic Diseases, 2016
Figure 2: Incidence of Gonorrhea, by Country, 2015-2018
Figure 3: U.S. Funding Trends, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2019
Figure 4: Global Market for STD Therapeutics, 2019-2025
Figure 5: Global Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 6: Global Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 7: Global Historic and Current Chlamydia Trend and Incidence in Women, by Country, 2016-2018
Figure 8: Global Incidence of Gonorrhea in Men, by Country, 2015-2017
Figure 9: Hepatitis Timeline, 1990-2004
Figure 10: Hepatitis Timeline, 2011-2015
Figure 11: Hepatitis Timeline, 2015-2017
Figure 12: Global Market for Hepatitis Therapeutics, 2019-2025
Figure 13: Global Market for Hepatitis Therapeutics, by Region, 2019-2025
Figure 14: Global Market for HIV/AIDS Therapeutics, 2019-2025
Figure 15: Global Market for HIV/AIDS Therapeutics, by Region, 2019-2025
Figure 16: U.S. Incidence of Syphilis Among Newborns, 2016-2018
Figure 17: Global Market for Other Therapeutics, 2019-2025
Figure 18: Global Market for Other Therapeutics, by Region, 2019-2025
Figure 19: Global Market for STD Diagnostics, 2019-2025
Figure 20: Global Market for STD Diagnostics, by Region, 2019-2025
Figure 21: Global Market Shares of STD Diagnostics, by Test Type, 2019
Figure 22: Global Market Shares of STD Diagnostics, by Test Type, 2025
Figure 23: Global Market for EIA and ELISA Diagnostics, 2019-2025
Figure 24: Global Market for PCR Diagnostics, 2019-2025
Figure 25: Global Market for RDT Diagnostics, 2019-2025
Figure 26: Global Market for Other Diagnostics, 2019-2025
Figure 27: Global Market for Antibiotic Drugs, 2019-2025
Figure 28: Global Market for Antibiotic Drugs, by Region, 2019-2025
Figure 29: Global Market for Antiviral/Antiretroviral Drugs, 2019-2025
Figure 30: Global Market for Antiviral/Antiretroviral Drugs, by Region, 2019-2025
Figure 31: Global Market for Other Drug Classes, 2019-2025
Figure 32: Global Market for Other Drug Classes, by Region, 2019-2025
Figure 33: North American Market for STD Therapeutics, 2019-2025
Figure 34: North American Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 35: North American Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 36: North American Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 37: North American Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 38: North American Market for STD Therapeutics, by Country, 2019-2025
Figure 39: U.S. Incidence of STDs, 2018
Figure 40: U.S. Sexually Transmitted Infections, by Sex, 2018
Figure 41: U.S. Historic and Current Syphilis Trends and Incidence, 2000-2018
Figure 42: U.S. Historic and Current Chlamydia Trends and Incidence, 2000-2018
Figure 43: U.S. Historic and Current Gonorrhea Trends and Incidence, 2000-2018
Figure 44: U.S. Historic and Current Hepatitis A Trends and Incidence, 2013-2018
Figure 45: U.S. Historic and Current Acute Hepatitis B Trends and Incidence, 2013-2018
Figure 46: U.S. Historic and Current Hepatitis C Trends and Incidence, 2013-2018
Figure 47: U.S. Historic and Current HIV Trends and Incidence, 2011-2018
Figure 48: U.S. Market for STD Therapeutics, 2019-2025
Figure 49: Canadian Sexually Transmitted Infections, by Sex, 2018
Figure 50: Canadian Historic and Current Chlamydia Trends and Incidence, 2008-2018
Figure 51: Canadian Historic and Current Gonorrhea Trends and Incidence, by Sex, 2008-2018
Figure 52: Canadian Historic and Current Infectious Syphilis Trends and Incidence, 2008-2018
Figure 53: Canadian Historic and Current Congenital Syphilis Trends and Incidence, 2008-2018
Figure 54: Canadian Market for STD Therapeutics, 2019-2025
Figure 55: Mexican Market for STD Therapeutics, 2019-2025
Figure 56: European Historic and Current Chlamydia Trends and Incidence, by Country, 2014-2018
Figure 57: European Historic and Current AIDS Trends and Incidence, by Country, 2014-2018
Figure 58: European Market for STD Therapeutics, 2019-2025
Figure 59: European Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 60: European Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 61: European Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 62: European Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 63: European Market for STD Therapeutics, by Country, 2019-2025
Figure 64: U.K. Incidence of HIV among Gay and Bisexual Men, 2015-2018
Figure 65: U.K. Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 66: U.K. Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 67: U.K. Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 68: U.K. Market for STD Therapeutics, 2019-2025
Figure 69: German Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 70: German Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 71: German Market for STD Therapeutics, 2019-2025
Figure 72: French Historic and Current Chlamydia Trends and Incidence, 2012-2017
Figure 73: French Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 74: French Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 75: French Market for STD Therapeutics, 2019-2025
Figure 76: Spanish Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 77: Spanish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 78: European Centre for Disease Prevention and Control: Annual Epidemiological Report
Figure 79: Spanish Market for STD Therapeutics, 2019-2025
Figure 80: Italian Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 81: Italian Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 82: Italian Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 83: Italian Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 84: Italian Market for STD Therapeutics, 2019-2025
Figure 85: Denmark’s Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 86: The Netherlands Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 87: Denmark’s Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 88: Irish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 89: The Netherlands Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 90: Swedish Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 91: Swedish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 92: Polish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 93: Rest of European Market for STD Therapeutics, 2019-2025
Figure 94: Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 95: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 96: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 97: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 98: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 99: Asia-Pacific Market for STD Therapeutics, by Country, 2019-2025
Figure 100: Chinese Market for STD Therapeutics, 2019-2025
Figure 101: Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2017
Figure 102: Japanese Market for STD Therapeutics, 2019-2025
Figure 103: Indian Historic and Current HIV Trends and Incidence, 2005-2018
Figure 104: Indian Historic and Current HIV Trends and Prevalence, 2005-2018
Figure 105: Indian Historic and Current AIDS Mortality, 2005-2018
Figure 106: Indian Market for STD Therapeutics, 2019-2025
Figure 107: South Korean Historic and Current HIV/AIDS Infections and Incidence, 2001-2018
Figure 108: South Korean Market for STD Therapeutics, 2019-2025
Figure 109: Rest of Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 110: South American, Middle Eastern and African Market for STD Therapeutics, 2019-2025
Figure 111: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 112: South American, Middle Eastern and Africa Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 113: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 114: Abbott Laboratories: Revenue Share, by Region, 2019
Figure 115: Abbott Laboratories: Revenue Share, by Business Segment, 2019
Figure 116: AbbVie Inc.: Revenue Share, by Country, 2019
Figure 117: Agilent Technologies Inc.: Revenue Share, by Region, 2019
Figure 118: Agilent Technologies Inc.: Revenue Share, by Business Segment, 2019
Figure 119: Becton, Dickinson and Co.: Financial Performance, 2013-2019
Figure 120: Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2019
Figure 121: Becton, Dickinson and Co.: Revenue Share, by Region, 2019
